Literature DB >> 32159726

Evaluation of Cyclosporine for the Treatment of DRESS Syndrome.

Emily Nguyen1,2, Daniel Yanes1, Sotonye Imadojemu3, Daniela Kroshinsky3.   

Abstract

Entities:  

Year:  2020        PMID： 32159726      PMCID： PMC7066519          DOI： 10.1001/jamadermatol.2020.0048

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  6 in total

1.  Cyclosporine Treatment of Drug-Induced Hypersensitivity Syndrome.

Authors:  Mark G Kirchhof; Aaron Wong; Jan P Dutz
Journal:  JAMA Dermatol       Date:  2016-11-01       Impact factor: 10.282

2.  Cyclosporine treatment of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report and brief review of the literature.

Authors:  Stephanie L Kuschel; Matthew S Reedy
Journal:  Pract Dermatol       Date:  2018-10

3.  Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases.

Authors:  Yi-Chun Chen; Hsien-Ching Chiu; Chia-Yu Chu
Journal:  Arch Dermatol       Date:  2010-08-16

4.  [Cyclosporin A inhibits interleukin 5 (IL-5) production from human peripheral lymphocytes].

Authors:  T Kimura; F Kokubu; S Horikoshi; H Tokunaga; T Imai; S Mita; M Adachi
Journal:  Arerugi       Date:  1994-05

Review 5.  Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update.

Authors:  S Tas; T Simonart
Journal:  Dermatology       Date:  2003       Impact factor: 5.366

6.  Efficacy of cyclosporine A as monotherapy in patients with psoriatic arthritis: a subgroup analysis of the SYNERGY Study.

Authors:  Delia Colombo; Sergio Chimenti; Paolo A Grossi; Antonio Marchesoni; Rosario Foti; Piergiacomo Calzavara-Pinton; Emanuela Zagni; Alessandra Ori; Gilberto Bellia
Journal:  G Ital Dermatol Venereol       Date:  2016-02-02       Impact factor: 2.011
  6 in total
  6 in total

1.  Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.

Authors:  Natsumi Hama; Riichiro Abe; Andrew Gibson; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2022-02-15

2.  Benralizumab: a potential tailored treatment for life-threatening DRESS in the COVID-19 era.

Authors:  Farah Mesli; Maëlle Dumont; Angèle Soria; Matthieu Groh; Matthieu Turpin; Guillaume Voiriot; Cedric Rafat; Delphine Staumont Sallé; Aude Gibelin; Cyrielle Desnos
Journal:  J Allergy Clin Immunol Pract       Date:  2021-07-14

Review 3.  Updates and Insights in the Diagnosis and Management of DRESS Syndrome.

Authors:  Elisa Maria Schunkert; Sherrie Jill Divito
Journal:  Curr Dermatol Rep       Date:  2021-11-09

4.  Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.

Authors:  Enrico Ammirati; Emanuele Bizzi; Giacomo Veronese; Matthieu Groh; Caroline M Van de Heyning; Jukka Lehtonen; Marc Pineton de Chambrun; Alberto Cereda; Chiara Picchi; Lucia Trotta; Javid J Moslehi; Antonio Brucato
Journal:  Front Med (Lausanne)       Date:  2022-03-07

5.  Treatment with IL5-/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS).

Authors:  Anna Gschwend; Arthur Helbling; Laurence Feldmeyer; Ulrich Mani-Weber; Cordula Meincke; Kristine Heidemeyer; Simon Bossart; Lukas Jörg
Journal:  Allergo J Int       Date:  2022-08-23

6.  Drug rash with eosinophilia and systemic symptoms syndrome masquerading as a lymphoproliferative disorder in a young adult on immunosuppressive therapy for rheumatoid arthritis: a case report.

Authors:  Elise Hyser
Journal:  J Med Case Rep       Date:  2022-09-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.